

NCT03082573 comparison:

Summary:
CHIA has 3 criteria while your personal folder has 3 criteria
Total found criteria: 2/3
Total not Found: 1/3
Total Extra: 8
This trial is INVALID



╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╕
│ CHIA Criteria                                     │ Matching Personal Criteria                        │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╡
│ Fluent in reading and writing in English language │ Fluent in reading and writing in English language │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ = 21 years of age at the time of participation    │ ≥ 21 years of age at the time of participation    │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ NA                                    │
╘═══════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Patients with diagnosis of RA with incomplete or failure to treatment described as either A or B A:  │
│ Failure to achieve remission or low disease activity within 3 to 6 months of treatment with          │
│ combination of methotrexate or other DMARDs therapy with a biologic DMARD in maximally tolerated     │
│ doses within the usual therapeutic range                                                             │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Presence if contraindications for treatment with H.P. Acthar gel including but not limited to any    │
│ known history of scleroderma, osteoporosis, systemic fungal infections, ocular Herpes Simplex,       │
│ recent administration of live or live attenuated vaccine (prior 6 months), recent surgery (prior 6   │
│ months), history of or the presence of a peptic ulcer, primary adrenocortical insufficiency, adrenal │
│ cortical hyperfunction; congestive heart failure (defined as New York Hear Association Functional    │
│ Class I to IV, uncontrolled hypertension                                                             │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Previous history of sensitivity to porcine protein products                                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Previous use of ACTH preparations for treatment of nephrotic syndrome (including but not limited to  │
│ H.P. Acthar gel and Synacthen®)                                                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 21 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Pregnancy                                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Previous history of sensitivity to ACTH preparations (including but not limited to H.P. Acthar gel   │
│ and Synacthen®)                                                                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ B- A requirement, in addition to DMARDs and biologic DMARDs, for chronic glucocorticoid therapy in a │
│ dose of greater than about 5 to 7.5 mg/day of prednisone or equivalent to achieve or maintain        │
│ remission or low disease activity after 3 to 6 months of treatment                                   │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛